In Australia, there is a paucity of coordinated strategies for preventing, detecting, and managing NAFLD
Despite being the most frequent cause of chronic liver disease in Australia, the prevalence and clinical consequences of non‐alcoholic fatty liver disease (NAFLD) remain uncertain.1 Accurate population‐based data on the burden of NAFLD are crucial for guiding public health strategies and directing health care resources to reducing the incidence of NAFLD and associated metabolic conditions.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Mahady SE, Adams LA. Burden of non‐alcoholic fatty liver disease in Australia. J Gastroenterol Hepatol 2018; 33 (Suppl 1): 1–11.
- 2. Roberts SK, Majeed A, Glenister K, et al. High prevalence of non‐alcoholic fatty liver disease in regional Victoria: a prospective population‐based study. Med J Aust 2021; 215: 77–82.
- 3. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11–20.
- 4. European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL‐EASD-EASO clinical practice guidelines for the management of non‐alcoholic fatty liver disease. J Hepatol 2016; 64: 1388–1402.
- 5. Cuthbertson DJ, Weickert MO, Lythgoe D, et al. External validation of the fatty liver index and lipid accumulation product indices, using 1H‐magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin‐resistant individuals. Eur J Endocrinol 2014; 171: 561–569.
- 6. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease: meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
- 7. Angulo P, Kleiner DE, Dam‐Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long‐term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389–397.e10.
- 8. Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology 2019; 70: 1521–1530.
- 9. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019; 156: 1717–1730.
- 10. Eslam M, Sarin SK, Wong VWS, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020; 14: 889–919.
- 11. McPherson S, Stewart SF, Henderson E, et al. Simple non‐invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non‐alcoholic fatty liver disease. Gut 2010; 59: 1265–1269.
Lucy Gracen is supported by a PA Research Foundation research award (2021).
Elizabeth Powell has received an unrestricted grant from Siemens Healthineers.